Pfizer Rated First By Most Doctors

27 January 1997

For the second year in a row, Pfizer has been rated first by US doctorsin nine specialty areas: general/family practitioners, internal medicine specialists, cardiologists, obstetricians/gynecologists, pediatricians, general surgeons, orthopedic surgeons, gastroenterologists and psychiatrists. The ratings are from pharmaceutical consulting firm Scott-Levin's Sales Force Structures & Strategies 1996. A total of 28 physician specialty groups were surveyed for the study.

New product launches, new indications and new formulations of existing drugs also helped Pfizer maintain the top spot among the nine core doctor specialty groups, it was noted. And Pfizer was also rated the top sales force by general practitioners for the second consecutive year.

Other leaders among the doctors' (according to their specialties) are: Merck & Co, internists, cardiologists and general surgeons; Wyeth, orthopedic surgeons; Ross, pediatricians; Astra-Merck, gastroenterologists; and Lilly, psychiatrists.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight